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Abstract
Background: Although practice guidelines recommend surgery for patients with severe chronic is-
chemic mitral regurgitation (CIMR), they do not specify whether to repair or replace the mitral valve. 
The purpose of this study was to evaluate the long-term outcomes in patients with severe CIMR under-
going mitral valve annuloplasty (MVA) versus subvalvular sparing mitral valve replacement (MVR).
Methods: 392 consecutive patients who underwent MVA or subvalvular sparing MVR for treatment 
of severe CIMR  were retrospectively reviewed.
Results: After adjustment for baseline differences with multivariable regression analysis at 53 months 
follow-up (interquartile range, 34–81 months), there was no significant difference between the two 
groups for risk of major adverse cardiac or cerebrovascular events (MACCE), cardiac death, or all-cause 
death.  Propensity score matching extracted 77 pairs. During the follow-up, compared with the MVR 
group, both the left atrium and left ventricle end-diastolic diameter were markedly larger (p = 0.013 
and p = 0.033, respectively), and the incidence of mitral regurgitation recurrence was significantly 
higher in the MVA group (p < 0.001). No significant difference was observed between the two propensity 
score-matched groups in composite in-hospital outcomes, overall survival, freedom from cardiac death 
or MACCE, except subvalvular sparing MVR was associated with a lower incidence of hospitalization 
for heart failure than MVA (p = 0.015). 
Conclusions: Subvalvular sparing MVR is a suitable management of patients with severe CIMR, it 
is more favorable to ventricular remodeling and is associated with a lower incidence of hospitalization 
for heart failure than MVA. (Cardiol J 2019; 26, 3: 265–274)
Key words: chronic ischemic mitral regurgitation, mitral valve annuloplast, subvalvular 
sparing mitral valve replacement, coronary artery bypass grafting 
Introduction
Chronic ischemic mitral regurgitation (CIMR) 
is common and is associated with worse long-term 
survival and functional status [1]. It is gener-
ally agreed that severe mitral regurgitation (MR) 
requires mitral valve intervention, but the opti-
mal management of patients with severe CIMR, 
specifically the choice between mitral valve an-
nuloplasty (MVA) and mitral valve replacement 
(MVR), has long been debated [2–5]. To date, there 
are no prospective randomized trials evaluating 
265www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
2019, Vol. 26, No. 3, 265–274
DOI: 10.5603/CJ.a2018.0006 
Copyright © 2019 Via Medica
ISSN 1897–5593ORIGINAL ARTICLE
the long-term outcomes of MVA versus MVR for 
severe CIMR, while published series have provided 
a wide range of results for long-term outcomes. 
Considering the different conclusions which might 
have been derived from heterogeneity of patient 
cohorts and methods of treatment, the present 
study is a long-term design and propensity score 
(PS) matched analysis to evaluate the effective-
ness of MVA versus sub-valvular sparing MVR 
for severe CIMR.
Methods
Patients and study design
This study was approved by the Human Re-
search Ethics Committee of the Fuwai Hospital and 
was performed in accordance with the Declaration 
of Helsinki and approved guidelines. CIMR was 
defined by coronary angiographic and echocardio-
graphic findings according to accepted criteria, i.e., 
1) MR occurring more than 16 days after myocar-
dial infarction; 2) type I/IIIb leaflet dysfunction 
following Carpentier’s classification; and 3) 70% 
or greater stenosis of at least one coronary artery, 
with wall motion abnormalities of the correspond-
ing left ventricular (LV) segment [3].
Between January 2003 and December 2014, 
a total of 1040 patients with CIMR were hospital-
ized to undergo coronary artery bypass grafting 
(CABG) combined with MVA or MVR. From the 
initial cohort, 642 patients were excluded for 
various reasons [3], i.e., 1) Preoperative MR ≤ 2+, 
congenital valvular heart disease, rheumatic or 
degenerative valvular disease, infective endo-
carditis, presence of aortic valve regurgitation or 
stenosis, emergency surgery, repeat operation; or 
2) Performance of other procedures, such as LV 
reconstruction/reshaping, partial band/pericardial 
annuloplasty, or procedures other than mitral ring 
annuloplasty for treatment. Moreover, the patients 
who underwent MVR without preserving the sub-
valvular apparatus were excluded. In addition, 
6 were lost to follow-up. Thus, the final study co-
hort comprised 392 patients: 306 (78.1%) patients 
underwent MVA whereas 86 (21.9%) underwent 
subvalvular sparing MVR.
Baseline patient characteristics, echocardiogra-
phy data, operative data, and surgical techniques were 
collected from the division of cardiovascular surgery 
database and individual medical records. Patients were 
followed up through the internet or by telephone in-
terview and outpatient department records.
Surgical technique
All surgical procedures were performed with 
standard bypass techniques through median ster-
notomy by senior surgeons with a special interest 
in mitral valve surgery. The decision to perform 
MVA or subvalvular sparing MVR was at the sur-
geon’s discretion. Downsizing ring annuloplasty 
(2 sizes) was used in all patients subjected to MVA. 
The ring size was determined by measurements 
of the intertrigonal distance and anterior leaflet 
height. Intraoperative transesophageal echocardi-
ography was routinely used. A successful MVA was 
defined as a leaflet coaptation of ≥ 0.8 cm and MR ≤ 1 
at transesophageal echocardiography performed 
at the end of cardiopulmonary bypass [3, 6]. Sub-
valvular apparatus were preserved when perform-
ing MVR, including posterior leaflet preservation, 
posterior and partial anterior leaflet preservation 
and both leaflet preservation. The decision to per-
form which kind of procedure was at the surgeon’s 
discretion according to situational conditions. The 
posterior mitral valve leaflet was left intact in all 
patients undergoing MVR. In 8 of patients undergo-
ing MVR, the middle portion of the anterior leaflet 
was resected and the remaining leaflet tissue was 
plicated with individual valve sutures. In 23 patients 
undergoing MVR, the anterior leaflet of the valve 
was partly or completely detached from the mitral 
annulus and divided in the middle at the 12 o’clock 
position, and the leftward portion of the anterior 
leaftlet was plicated to the anterolateral commis-
sure with a pledgetted 4–0 polypropylene suture. 
The rightward a portion of the anterior mitral leaflet 
was similarly plicated to the posteromedial commis-
sure. Complete revascularization was achieved in 
all patients with arterial conduits or saphenous vein 
grafts. All patients received the same perioperative 
care and medical therapy according to guidelines.
Echocardiography
Two-dimensional and Doppler transthoracic 
echocardiography examinations were performed 
before operations and at pre-discharge for all 
patients. MR was classified as mild (grade 1+), 
moderate (grade 2+), or severe (grades 3+ and 
4+) [7]. LV inferior basal wall motion abnormal-
ity (BWMA) includes hypokinesia, dyskinesis and 
aneurysm. Echocardiographic criteria for aneurysm 
were evidence of thinning and localized LV dila-
tion or distortion. Dyskinesis was the presence 
of outward displacement of the LV wall during 
systole [8, 9].
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Statistical analysis 
All statistical analyses were performed by 
SPSS version 20 (IBM SPSS Inc., Chicago, IL), SAS 
software version 9.2 (SAS Institute) and Graph Pad 
Prism release 5 (Graph Pad Software Inc., La Jolla, 
Calif) statistical packages. All reported p values are 
two sided, and values of p < 0.05 were considered 
to indicate statistical significance. Continuous data 
are shown as  mean ± standard deviation. The 
Student t test was used to measure the differences 
for variables with a normal distribution and equal 
variances. The Wilcoxon rank sum test was used 
for non-normally distributed variables. Categorical 
data are displayed as frequencies and percentages 
and comparisons were made with c2 tests (Fisher 
exact tests if appropriate). A stepwise multivariable 
Cox proportional hazards model was developed to 
determine the independent risk factors. Variables 
with a p value less than 0.10 in the univariate 
analyses were entered into multivariable models. 
Differences in risk-adjusted, long-term rates of 
study outcomes among patients who underwent 
different surgical procedures were assessed by 
the use of multivariable Cox proportional hazards 
regression with adjustment for all patient-level 
variables in Table 1. Cumulative event rates were 
calculated using a Kaplan-Meier method, and dif-
ferent event curves of outcomes were compared 
using a log-rank test.
To reduce the impact of treatment selection 
bias and potential confounding in the observational 
study,  rigorous adjustment for baseline differences 
by use of propensity score matching was performed 
[10]. A PS representing the probability of having 
subvalvular sparing MVR as opposed to MVA was 
calculated for each patient by using a non-parsi-
monious multivariable logistic regression model. 
Variables used in the model are shown in Table 1. 
Pairs of patients with MVA and sub-valvular spar-
ing MVR were matched using calipers of width 0.2 
standard deviations of  logit of the PS [11]. Model 
discrimination was assessed with C statistics, and 
model calibration was assessed with Hosmer-
Lemeshow statistics. Finally, 77 pairs of patients 
were matched to obtain risk-adjusted outcome 
comparisons between the two groups.
Results
Patient characteristics
The demographic, clinical and procedural data 
of patients who underwent MVA and subvalvular 
sparing MVR before and after PS matching are il-
lustrated in Table 1. Before matching, patients who 
underwent subvalvular sparing MVR were older, 
with a worse mitral regurgitation grade and better 
left ventricular ejection fraction (EF).
Three kinds of complete symmetric rings were 
used in the present study, with the median size of 
28 mm (interquartile range, 28–29 mm): Duran 
Ancore (Medtronic, Santa Ana, CA), Carpentier-
Edwards Physio ring I (Edwards Lifesciences, 
Irvine, CA), Carpentier-Edwards Physio ring II 
(Edwards Lifesciences, Irvine, CA). There were 
seven types of prosthetic valves, with a median 
size of 27 mm (interquartile range, 27–29 mm). 
The rate of bioprosthesis was 46.5% (40/86). Three 
types of bioprostheses were used (n = 40): Mosaic 
(Medtronic, Santa Ana, CA), Carpentier-Edwards 
Perimount (Edwards Lifesciences, Irvine, CA) 
and Hancock II (Medtronic, Santa Ana, CA). Four 
types of mechanical valves were used (n = 46): 
Medtronic Open Pivot (Medtronic, Minneapolis, 
MN), On-X valve (On-X Life Technology, Austin, 
TX), CarboMedics Mechanical (Sorin-CarboMedics 
Inc, Italia, S.r.l) and St. Jude valve (St. Jude Medi-
cal, Minneapolis, MN). Subvalvular apparatus were 
preserved when performing MVR, with posterior 
leaflet preservation in 55 (64.0%) patients, poste-
rior and partial anterior leaflet preservation in 
8 (9.3%) patients, and both leaflets preservation in 
23 (26.7%) patients.
Follow-up and outcomes
The clinical follow-up was closed on January 1, 
2017. The median follow-up was 53 months (inter-
quartile range, 34–81 months) with a completion 
rate of 98.5% (392/398) in the overall cohort. Dur-
ing follow-up, 62 (15.8%) patients died, of whom 
53 (13.5%) died of a cardiac cause. The overall 
survival rates at 5 and 10 years were 86.6% and 
52.9%, respectively. Freedom from cardiac death at 
5 and 10 years were 88.1% and 63.9%, respectively. 
After adjustment for baseline differences with 
Cox proportional hazard model analysis, there was 
no significant difference between MVA and subval-
vular sparing MVR in risks of major adverse cardiac 
or cerebrovascular events (MACCE: cardiac death, 
repeat revascularization and myocardial infarction, 
stroke, subsequent mitral valve surgery, or hospi-
talization for heart failure), cardiac death, or overall 
death (for MACCE: p = 0.063; for cardiac death: 
p = 0.549; and for overall death: p = 0.759) (Table 2).
Risk factor analysis
Multivariable analysis showed that age and 
preoperative EF were independent predictors of 
overall death (for age: hazard ratio [HR], 1.03; 95% 
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confidence interval [CI] 1.01–1.07, p = 0.030; and 
for EF: HR 0.96; 95% CI 0.94–0.98, p < 0.001), 
while the number of grafts and preoperative 
EF were independent predictors of MACCE (for 
the number of grafts: HR 1.48; 95% CI 1.11–1.97, 
p = 0.012; and for EF: HR 0.96; 95% CI 0.94–0.97, 
p < 0.001). Of note, the choice of MVA or subval-
vular sparing MVR was not a significant predic-
tor of late overall death or MACCE (p = 0.997 
and p = 0.260, respectively) (Table 3).
Results of propensity score matching analysis
After PS matching, 77 pairs were extracted 
by 1:1 manner using nearest neighbor matching 
without replacement. Late deaths occurred in 
29 patients, including 26 cardiac deaths. The 5- and 
10-year overall survival rates were 80.9% and 
55.8%, respectively. The 5- and 10-year freedom 
from cardiac death rates were 82.5% and 62.1%, 
respectively. There were no differences in preop-
erative and operative characteristics between the 
PS-matched patients (Table 1). The incidences 
of composite in-hospital outcomes (stroke, re-
operation for bleeding, application of intra-aortic 
balloon pump and acute renal failure) were similar 
between the two PS-matched groups (Table 4). 
During follow-up, compared with the MVR group, 
both the left atrium and left ventricle end-diastolic 
diameter were markedly larger (p = 0.013 and 
p = 0.033, respectively), and the incidence of MR 
Table 2. Long-term outcomes according to different surgical procedures in the overall population.
MVA MVR Adjusted HR# (95% CI) P 
All patients 306 86
Cardiac death 41 (13.4%) 12 (14.0%) 1.25 (0.60–2.62) 0.549
Overall death 50 (16.3%) 12 (14.0%) 0.90 (0.44–1.82) 0.759
MACCE 82 (26.8%) 14 (16.3%) 0.55 (0.29–1.03) 0.063
#Multivariable Cox proportional hazard analysis was used with adjustment for all patient-level variables (Indicated by*) in Table 1. The HRs 
were reported for MVA with MVR as reference; HR — hazard ratio; CI — confidence interval; MACCE — major adverse cardiac and cerebro-
vascular event; MVA — mitral valve annuloplasty; MVR — mitral valve replacement.
Table 3. Cox proportional hazard analysis for overall death and major adverse cardiac and cerebro-
vascular event (MACCE) at long-term follow-up.
Predictors Univariable Multivariable
P HR (95% CI) P HR (95% CI)
Predictors of overall death:
Surgical procedures* 0.895 0.96 (0.51–1.80) 0.997
Age 0.032 1.03 (1.01–1.07) 0.030 1.03 (1.01–1.07)
EF < 0.001 0.96 (0.94–0.98) < 0.001 0.96 (0.94–0.98)
Grafts/patient 0.045 1.41 (1.01–1.96) 0.243
Anastomoses/patient 0.083 1.24 (0.97–1.57) 0.351
Predictors of MACCE:
Surgical procedures* 0.119 0.64 (0.36–1.12) 0.260
Age 0.031 1.03 (1.00–1.05) 0.055
History of heart failure 0.010 1.72 (1.14–2.60) 0.337
Ventricular arrhythmia 0.028 2.17 (1.09–4.31) 0.064
EF < 0.001 0.95 (0.94–0.97) < 0.001 0.96 (0.94–0.97)
BWMA 0.004 1.88 (1.23–2.87) 0.357
Left ventricular aneurysm 0.066 1.77 (0.96–3.25) 0.823
Grafts/patient <0.001 1.66 (1.25–2.20) 0.012 1.48 (1.11–1.97)
Anastomoses/patient 0.004 1.33 (1.10–1.61) 0.875
*Indicates mitral valve annuloplasty or replacement; HR — hazard ratio; CI — confdence interval; EF — left ventricular ejection fraction; 
BWMA — left ventricular inferior basal wall motion abnormality
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recurrence was significantly higher in the MVA 
group (p < 0.001) (Table 5). There were no signifi-
cant differences in overall survival, freedom from 
cardiac death or MACCE between the two groups 
(all p > 0.05), except for a higher incidence of 
hospitalization for heart failure in the PS-matched 
MVA group than in the subvalvular sparing MVR 
group (p = 0.015) (Fig. 1).
Discussion
According to practice guidelines, both MVA and 
MVR are recommended treatments for correction 
of severe ischemic MR [12]. However, an optimal 
surgical approach to treatment of severe ischemic 
MR remains controversial. Clinical studies have sug-
gested that repair is associated with lower periop-
erative morbidity and mortality but has a higher risk 
of recurrence, which confers with a predisposition 
to atrial fibrillation, heart failure, and readmission, 
whereas replacement provides higher periopera-
tive mortality but better long-term correction with 
a lower risk of recurrence [13–15]. When MVR is 
required, chordal sparing is the preferred technique. 
Okita et al. [16] and David et al. [17] reported that 
the subvalvular apparatus preservation results in 
improved LV function and enhanced survival. Pres-
ervation of the mitral subvalvular apparatus led to 
better postoperative LV function and survival than 
those after apparatus removal.
In the present study, no difference was ob-
served in the incidences of early mortality or 
postoperative complications between the two 
PS-matched groups. Published literature provides 
a wide range of results in terms of early outcomes. 
Several recent experiences found no significant 
difference between the two surgical manage-
ments, this is in accordance with the present 
observations [2, 18], whereas several studies 
showed that mitral valve repair is associated 
with lower operative mortality and postoperative 
complications [19, 20]. 
Table 4. Early clinical outcomes of propensity score-matched patients.
Variables MVA (n = 77) MVR (n = 77) P 
Composite in-hospital outcome 9 15 0.183
In-hospital mortality 1 (1.3%) 2 (2.6%) 0.556
Complications: 8 (10.4%) 13 (16.9%) 0.240
Stroke 0 (0%) 0 (0%) –
Reoperation for bleeding 1 (1.3%) 3 (3.9%) 0.300
Postoperative IABP 3 (3.9%) 3 (3.9%) > 0.999
Respiratory complication 3 (2.5%) 5 (7.4%) 0.138
Acute renal failure 1 (1.3%) 2 (2.6%) 0.556
MVA — mitral valve annuloplasty; MVR — mitral valve replacement; IABP — intra-aortic balloon pump
Table 5. Perioperative and follow-up echocardiographic results of propensity score-matched patients.
Variables MVA (n = 77) MVR (n = 77)
Preoperative Postoperative Follow-up Preoperative Postoperative Follow-up
EF [%] 54.42 ± 11.42 52.81 ± 8.68 52.29 ± 8.23 55.22 ± 9.87 52.62 ± 8.62 51.95 ± 9.58
LVEDD  
mid-ventricle [mm]
59.30 ± 6.25 51.02 ± 6.61 55.91 ± 5.23 58.51 ± 6.11 51.32 ± 8.25 53.75 ± 6.99*
LA [mm] 44.48 ± 6.54 38.32 ± 4.76 45.34 ± 5.82 43.68 ± 7.53 39.34 ± 7.66 42.76 ± 6.25*
Mitral regurgitation: – – 41 (53.25%) – 2 (2.60%)*
Moderate – – 32 (41.56%) – 2 (2.60%)
Severe – – 9 (11.69%) – 0 (0%)
Periprosthetic leak – – – – 1 (1.30%)
*p < 0.05 vs. MVA; MVA — mitral valve annuloplasty; MVR — mitral valve replacement; EF — left ventricular ejection fraction; LVEDD — left 
ventricular end-diastolic dimension; LA — left atrial dimension
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After adjustment for baseline differences 
with Cox proportional hazard model analysis, the 
present long-term observational study showed 
no substantial difference between the two man-
agements of risk for MACCE, cardiac death, or 
overall death. Moreover, PS matching analysis 
also showed similar results. Follow-up echocar-
diographic results of PS-matched patients showed 
that, compared with the MVR group, both the left 
atrium and left ventricle end-diastolic diameter 
were markedly larger, and the incidence of MR 
recurrence was significantly higher in the MVA 
group. MVR provides a considerably more durable 
correction of MR than MVA [2, 19], which may 
have a beneficial effect on long-term outcomes. 
However, this effect must be weighed against any 
potential adverse consequences of a prosthetic 
Figure 1. Kaplan-Meier curves for (A) overall survival (B) freedom from cardiac death (C) freedom from MACCE and 
(D) freedom from hospitalization for heart failure in 1:1 propensity score-matched mitral valve annuloplasty group 
(gray lines) and mitral valve replacement group (black lines); MACCE — major adverse cardiac and cerebrovascular 
event (cardiac death, repeat revascularization and myocardial infarction, stroke, subsequent mitral valve surgery, or 
hospitalization for heart failure); MVA — mitral valve annuloplasty; MVR — mitral valve replacement.
valve, such as long-term thromboembolism, en-
docarditis, and structural valve deterioration [2]. 
The trial conducted by Goldstein et al. [2] showed 
that, at 2 years after either MVA or MVR for severe 
ischemic MR, there were no significant between-
group differences with respect to LV reverse 
remodeling, however, the rates of MR recurrence 
were significantly higher in the MVA group than 
in the subvalvular sparing MVR group (58.8% 
vs. 3.8%, p < 0.001), related to heart failure and 
cardiovascular admissions [2]. Another important 
study carried out by Lorusso  et al. [3] showed that 
8-year survival was 81.6% ± 2.8% vs. 79.6% ± 
± 4.8% in MVA and MVR, respectively (p = 0.42). 
Cohn et al. [21] reported a 5-year survival of 56% 
and 91.5% in MVA and MVR, respectively, whereas 
a meta-analysis showed that the relative long-term 
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risk of death was 35% higher in the MVR group 
than in the repair group [22].
 Such differing conclusions might have been 
derived from the heterogeneity of patient cohorts. 
Therefore, in the present study, only patients 
undergoing MVA or MVR with complete myocar-
dial revascularization were included, without con-
genital valvular heart disease, rheumatic valvular 
disease, infective endocarditis, presence of aortic 
valve regurgitation or stenosis, or having received 
other procedures. Moreover, the patients who un-
derwent MVR without preserving the subvalvular 
apparatus were excluded. In addition, a propensity 
score model was constructed to minimize effects 
Limitation of confounding variables which ensured 
the reliability of study results.
Limitations of the study
First, this study reports retrospective data 
from a single center and is subject to all the limi-
tations inherent to this design. The small study 
sample might have led to type II statistical errors. 
An appropriately powered, randomized, controlled 
trial evaluating the optimal management of CIMR 
would be useful inconfirming these results. Second, 
pre-, intra-, and postoperative information about 
the exact mechanisms and characteristics of MR 
were not available for all patients. For this reason, 
the objectives of this study were early and late 
outcomes. Third, selection bias should be intro-
duced at the time of decision to perform surgical 
approaches because the decision to perform MVR 
or MVA may be related to the complexity of the 
patient and experience of the surgeon. To minimize 
the effects of selection bias, a propensity score 
model was constructed. Fourth, because of the 
12 year inclusion time, there were three types of 
rings and seven types of prosthetic valves which 
could affect heterogeneity of the study. Another 
limitation is that, although this study assesses 
surgical approaches to the mitral valve, no detailed 
information was available regarding medical thera-
py at follow-up. However, with guideline-directed 
medical therapy by cardiologists, who had received 
systematic and standardized clinical training, the 
potential bias of therapy between groups is ex-
pected to be minimized.
Conclusions
The present study indicates that subvalvular 
sparing MVR was more favorable to ventricular 
remodeling and associated with a lower incidence 
of hospitalization for heart failure than MVA at 
follow-up. Therefore, subvalvular sparing MVR ap-
pears to be a suitable management for patients with 
CIMR undergoing mitral valve surgery and CABG. 
An appropriately powered, randomized, controlled 
trial evaluating the optimal management of CIMR 
would be useful in confirming the present results.
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